***Streptococcus pneumoniae*, *S. pyogenes*, and *S. agalactiae* membrane
phospholipid remodeling in response to human serum**

Luke. R. Joyce¹, Ziqiang Guan^{2#}, and Kelli L. Palmer^{1#}

¹Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX,
USA

²Department of Biochemistry, Duke University Medical Center, Durham, NC, USA

Running title: Phospholipid remodeling in pathogenic streptococci

#Corresponding authors

Ziqiang Guan: Ziqiang.Guan@duke.edu

Kelli Palmer: Kelli.Palmer@utdallas.edu

Keywords: Streptococcus, lipidomics, phospholipids, phosphatidylcholine,
plasmalogen, cellular membrane

Abstract

Streptococcus pneumoniae, *S. pyogenes* (Group A *Streptococcus*; GAS), and *S. agalactiae* (Group B *Streptococcus*; GBS) are major etiological agents of diseases in humans. The cellular membrane, a crucial site in host-pathogen interactions, is poorly characterized in streptococci. Moreover, little is known about whether or how environmental conditions influence their lipid compositions. Using normal phase liquid chromatography coupled with electrospray ionization mass spectrometry, we characterized the phospholipids and glycolipids of *S. pneumoniae*, GAS, and GBS in routine undefined laboratory medium, streptococcal defined medium, and, in order to mimic the host environment, defined medium supplemented with human serum. In human serum-supplemented medium, all three streptococcal species synthesize phosphatidylcholine (PC), a zwitterionic phospholipid commonly found in eukaryotes but relatively rare in bacteria. We previously reported that *S. pneumoniae* utilizes the glycerophosphocholine (GPC) biosynthetic pathway to synthesize PC. Through substrate tracing experiments, we confirm that GAS and GBS scavenge lysoPC, a major metabolite in human serum, thereby using an abbreviated GPC pathway for PC biosynthesis. Furthermore, we found that plasmanyl-PC is uniquely present in the GBS membrane during growth with human serum, suggesting GBS possesses unusual membrane biochemical or biophysical properties. In summary, we report cellular lipid remodeling by the major pathogenic streptococci in response to metabolites present in human serum.

Introduction

Streptococci are Gram-positive bacteria that natively colonize humans in niches including the oral cavity, the nasopharynx, and the genitourinary tract (1). Three species of streptococci, *Streptococcus pneumoniae*, *S. pyogenes* (Group A *Streptococcus*; GAS), and *S. agalactiae* (Group B *Streptococcus*; GBS), are considered major human pathogens, resulting in over 1.5 million deaths each year around the world (2,3). These pathogens cause a wide range of diseases of varying severity in all age groups, including streptococcal pharyngitis, soft tissue infections, pneumonia, meningitis, bacteremia, and necrotizing fasciitis (3–10).

The surface of the streptococcal cell is a critical interface for host interactions. Many studies into the pathogenicity of streptococci have focused on virulence factors including secreted proteins, surface polymers and adhesins, and mechanisms for sensing the extracellular environment (11–13). In contrast, little is known about the cellular membrane composition and dynamics of streptococci. Earlier studies mainly utilized thin layer chromatography (TLC) or column separation coupled with paper chromatography to study membrane lipids extracted from cultures in routine laboratory medium (14–19). However, these methods lack molecular specificity and sensitivity for the comprehensive characterization of membrane lipids (20). The phospholipids phosphatidylglycerol (PG) and cardiolipin (CL), and the glycolipids monohexosyldiacylglycerol (MHDAG) and dihexosyldiacylglycerol (DHDAG) were previously detected in all three streptococcal species (14–19,21–23).

We recently utilized normal phase liquid chromatography coupled with electrospray ionization mass spectrometry (NPLC-ESI/MS) to characterize the lipid membranes of the Mitis group streptococcal species *S. pneumoniae*, *S. mitis*, and *S. oralis*, and described for the first time the presence of the zwitterionic phospholipid phosphatidylcholine (PC) in these organisms (24,25). We further showed that the biosynthesis of PC in these organisms occurs through the rare glycerophosphocholine (GPC) pathway which relies upon scavenging of GPC and/or lysophosphatidylcholine (lysoPC) from the growth medium (24).

Here, we utilized NPLC-ESI/MS to characterize the membrane lipids of the three major streptococcal pathogens. To mimic the human host environment and to assess the effects of human serum on the membrane lipid compositions, the streptococci were cultured in defined medium with or without human serum supplementation. We show that: 1) human serum provides the substrates required for *S. pneumoniae* to synthesize PC; 2) the GAS and GBS scavenge the human metabolite lysoPC to synthesize PC via an abbreviated GPC pathway; and, 3) plasmalogen-PC (pPC) is uniquely present in the GBS membrane during culture with human serum.

Material and Methods

Bacterial strains, media, and growth conditions

Culture media and bacterial strains used in this study are shown in Table 1 and Table S1, respectively. Routine laboratory culture conditions for each species were 37°C for GBS, and 37°C and 5% CO₂ for *S. pneumoniae* and GAS. Rich culture media used were Todd-

Hewitt Broth for GBS and Todd-Hewitt Broth supplemented with yeast extract at 0.5% w/v for *S. pneumoniae* and 0.2% w/v for GAS. Streptococcal chemically defined medium (26) was diluted from stock as described (27) with 1% glucose, for GAS and GBS. For *S. pneumoniae*, defined medium was supplemented with 0.5 mM choline (25). Where appropriate, defined medium was supplemented with 5% v/v human serum (Sigma-Aldrich), 100 μ M GPC (Sigma-Aldrich), or 100 μ M lysoPC 20:0 (Avanti Polar Lipids). See Supplemental Text S1 for growth curve methodology.

GAS and GBS culture for lipidomic analysis

Single colonies of GAS and GBS were inoculated into 15 mL rich medium and incubated overnight as described above, until pelleting and storage for lipidomic analysis described below. For defined medium analysis, single colonies were cultured in defined medium overnight, diluted into 15 mL pre-warmed defined medium supplemented with or without 5% v/v human serum to an OD_{600nm} of 0.05, and incubated for 8 h before pelleting. Cultures were performed in biological triplicate.

***S. pneumoniae* culture for lipidomic analysis**

Single colonies of *S. pneumoniae* were inoculated into 6 mL rich medium, serially diluted, and incubated overnight as described. Cultures in early exponential phase were inoculated into 15 mL pre-warmed rich medium and cultured until early stationary phase. Overnight defined medium cultures were inoculated directly from freezer stocks and serially diluted for overnight growth. Early exponential phase cultures were inoculated into

defined medium supplemented with or without 5% v/v human serum at an OD_{600nm} of 0.05 and incubated for 8 h until pelleting. Cultures were performed in biological triplicate.

GPC and lysoPC supplementation experiments

Overnight defined medium cultures of GAS and GBS were diluted to a starting OD_{600nm} 0.05 in 15 mL defined medium supplemented with either 100 µM GPC or 100 µM lysoPC (20:0) and incubated for 8 h as described above. Cultures were pelleted and stored for lipidomic analysis. Cultures were performed in biological triplicate.

Lipidomics

Acidic Bligh-Dyer lipid extractions were performed as described (25,28). Normal-phase LC-ESI/MS was performed on an Agilent 1200 quaternary LC system equipped with an Ascentis silica high-performance liquid chromatography (HPLC) column (5 µm; 25 cm by 2.1 mm; Sigma-Aldrich) as described previously (25,28,29). See Supplemental Text S1 for more information.

Results

Pathogenic streptococci remodel their membrane phospholipid composition in response to human serum

The major phospholipids detected by normal-phase LC-ESI/MS for each streptococcal species and strain used in this study, when cultured in the rich, undefined laboratory medium Todd-Hewitt Broth (supplemented with yeast extract where appropriate), and in streptococcal defined medium supplemented with or without 5% v/v human serum, are

shown in Table 1. The biosynthetic pathways for these lipids are shown in Figure 1. Growth curves for streptococci cultured with or without 5% v/v human serum are shown in Supplemental Figure S1A-F. Human serum supplementation did not significantly alter the growth of the bacteria, except during late exponential and early stationary phase of *S. pneumoniae* D39 (Supplemental Figure S1A).

The lipid profile of *S. pneumoniae* cultured in Todd-Hewitt Broth supplemented with 0.5% w/v yeast extract consists of the major anionic phospholipids PG and CL, the zwitterionic phospholipid PC, and the glycolipids MHDAG and DHDAG (25). Figure 2A (panel 1) displays the positive ESI mass spectrum of PC (appearing at the retention time 19-20.5 min) in the membrane of *S. pneumoniae*. We previously determined that Todd-Hewitt Broth contains GPC, a substrate utilized by *S. pneumoniae* to synthesize PC (25). A similar phospholipid profile is observed for *S. pneumoniae* cultured in defined medium, except that PC is absent, due to the lack of GPC and lysoPC substrates in the medium (25). The total ion chromatogram (TIC) (Supplemental Figure S2) and mass spectrum (MS) of retention time 19-20.5 min of *S. pneumoniae* D39 grown in defined medium lacking human serum are shown in Figure 2A (panel 2), and no PC is present. However, *S. pneumoniae* synthesizes PC when defined medium is supplemented with 5% v/v human serum (Supplemental Figure S2). Figure 2A (panel 3) shows the ESI mass spectrum of the major PC species. These data demonstrate that human serum provides the substrates required for PC biosynthesis via the GPC pathway in *S. pneumoniae*.

The lipid profile of GAS cultured in Todd-Hewitt Broth supplemented with 0.2% w/v yeast extract is similar to that of *S. pneumoniae*, with the exception that PC is not detected (Table 3.1, Figure 2B [panel 1]). The lipid profile remains unchanged in defined medium, and no PC is detected (Figure 2B [panel 2] and Supplemental Figure S2). Interestingly, PC is observed in the membrane of GAS when defined medium is supplemented with 5% v/v human serum, indicating that human serum, but not Todd-Hewitt Broth or defined medium, provide substrates required for PC biosynthesis (Supplemental Figure S2). The ESI/MS of the major PC species identified in the GAS membrane is shown in Supplemental Figure S3. The chemical structure of PC (16:0/18:2) (with the M^+ ion at m/z 758) is shown in Supplemental Figure S3A and the supporting tandem mass spectrometry (MS/MS) fragmentation of m/z 758 is shown in Supplemental Figure S3B.

The lipid profile of GBS cultured in Todd-Hewitt Broth consists of MHDAG, DHDAG, PG, and CL, as well as the aminoacylated PG molecule lysyl-PG (Lys-PG), and a recently described novel, cationic glycolipid, Lysyl-Glucosyl-DAG (LGD) (Table 1, Supplemental Figure S2) (23). The lipidomic profile of the GBS is unchanged when cultured in defined medium (Table 1). Like GAS, the GBS do not synthesize PC when cultured in Todd-Hewitt Broth or defined medium (Figure 2C [panel 1 and panel 2]). Also, like GAS, GBS synthesize PC when defined medium is supplemented with 5% v/v human serum (Figure 2C [panel 3], Supplemental Figure S2). However, the ESI mass spectrum (Figure 2C [panel 3]) indicates a modified PC molecule that co-elutes off the column at the same time as Lys-PG. The modified PC molecule was determined to be the plasmalogen, plasmanyl-PC (pPC) (Supplemental Figure S3), in which the *sn*-1 acyl chain linkage is an ether bond,

instead of the ester bond that is present in diacyl PC (Supplemental Figure S3A and S3C). The identification of pPC is supported by MS/MS. Specifically, the m/z 482 ion in the MS/MS spectrum of m/z 720 (Supplemental Figure S3D) is consistent with the pPC structure, as compared to the m/z 496 ion in the MS/MS spectrum of m/z 758 for the diacyl PC (Supplemental Figure S3B).

Taken together, these data demonstrate that major pathogenic streptococci remodel their membrane lipid composition by synthesizing PC in response to metabolites present in human serum. Furthermore, plasmalogen-PC is uniquely observed in the membrane of the GBS during culture with human serum.

GAS and GBS scavenge lysoPC to form PC

Next, we sought to investigate if GAS and GBS utilize the GPC biosynthetic pathway previously identified in the Mitis group streptococci (25). GAS and GBS strains were cultured in defined medium supplemented with either 100 μ M GPC or 100 μ M lysoPC (20:0), a non-natural acyl chain length in these species, and lipidomic analysis was performed. These concentrations are physiologically relevant because lysoPC and GPC are present in varying concentrations throughout the human body at ≤ 200 μ M and ≤ 500 μ M, respectively (30,31). The ESI mass spectra are shown in Figure 3. When GAS is cultured in GPC-supplemented defined medium, very little PC is detected (Figure 3A). In defined medium supplemented with lysoPC (20:0), a substantial amount of PC is detected for GAS (Figure 3B). Similarly, when GBS is cultured in GPC-supplemented defined medium, no PC is detected (Figure 3C), and robust levels of PC are observed when GBS

are cultured in defined medium supplemented with lysoPC (20:0) (Figure 3D). Taken together, these data identify lysoPC, not GPC, as the primary substrate scavenged by the GAS and GBS to synthesize PC.

Discussion

The cellular membrane is a critical and dynamic surface of bacterial cells that plays a role in many cellular processes yet is largely understudied in streptococci. In this study we characterized the lipidome of the major streptococcal pathogens *S. pneumoniae*, GAS, and GBS when cultured in a standard rich laboratory medium (Todd-Hewitt Broth), and a defined medium supplemented with or without 5% v/v human serum. We show that all three streptococcal species remodel their cellular membrane in response to human metabolites, specifically, by synthesis of PC. To our knowledge, this is the first identification of PC and the plasmalogen pPC in the GAS and GBS, respectively. PC has been linked to virulence in certain bacteria (32,33). Streptococci may incorporate PC into their membranes as a form of eukaryotic membrane mimicry to evade immune defense, although this must be investigated further.

Human serum is a rich source of nutrients for streptococci. A major metabolite of human serum is lysoPC (30,34). *S. pneumoniae* utilizes a full GPC pathway (25), scavenging metabolites from human serum to synthesize PC. However, the GAS and GBS predominantly synthesize PC using an abbreviated GPC pathway, by primarily scavenging lysoPC from the exogenous environment. This is likely due to a missing or poorly expressed GPC transporter and/or the inability to acylate GPC to form lysoPC. The

ability of *S. pneumoniae* but not GAS or GBS to scavenge GPC could be capitalized upon in comparative genomic and laboratory experiments to help identify the GPC transporter in *S. pneumoniae*, which is currently unknown.

To our knowledge, the presence of the plasmalogen pPC in the GBS membrane has not been described before. To date, plasmalogens have only been observed in strict anaerobes such as *Clostridium* and *Bifidobacterium* (35–37). Biosynthesis of plasmalogens in bacteria is poorly understood, with the first bacterial desaturase involved in plasmenyl *sn*-1 vinyl ether bond formation and the first plasmalogen synthase, PlsAR, in *Clostridium perfringens* only recently identified (38,39). Plasmalogen lipids are thought to promote oxidative stress survival in animal cells (40,41) and may play a role in GBS pathogenesis. pPC has been detected in human blood at ~50 μ M in healthy adults (30,34). There are two possible pathways for the presence of pPC in the membrane of GBS during culturing with human serum. Either, 1) GBS scavenge the intermediate lyso-pPC, adding the second acyl chain, and/or full pPC directly from human serum or 2) *de novo* pPC synthesis is occurring. Our experimental design does not allow us to discriminate which pathway is utilized. Given that GBS lack an identifiable homolog of the *C. perfringens* PlsAR synthase, coupled with the lack of plasmalogen form of other common lipids, the pPC we identify in the membrane of GBS is likely derived from the plasmalogen lipids present in human serum. The origin and roles of pPC in GBS is a subject of further investigation.

Overall, this work demonstrates that culture medium can significantly alter the membrane lipid composition of major human streptococcal pathogens. This supports the significance of culturing pathogens in media that more closely represent the host environments in which the pathogens are found. Further investigation into the biosynthesis and mechanistic roles of PC in the membrane will likely provide novel insights into the pathogen-host interactions and pathogenesis of these streptococcal species.

Conflicts of interest

The author(s) declare that there are no conflicts of interest.

Funding information

The work was supported by grant R21AI130666 from the National Institutes of Health and the Cecil H. and Ida Green Chair in Systems Biology Science to K.P, grant R56AI139105 from the National Institutes of Health to K.P and Z.G., and grant U54GM069338 from the National Institutes of Health to Z.G.

Acknowledgements

We gratefully acknowledge Michael Federle at the University of Illinois at Chicago for providing *S. pneumoniae* D39.

References

1. Facklam R. What happened to the streptococci: Overview of taxonomic and nomenclature changes. *Clin Microbiol Rev.* 2002;15(4):613–30. doi:

270 10.1128/CMR.15.4.613-630.2002

271 2. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of Group A
272 Streptococcal diseases. *Lancet Infect Dis*. 2005;5(11):685–94. doi:
273 10.1016/S1473-3099(05)70267-X

274 3. CDC. Antibiotic resistance threats in the United States, 2019. [Internet]. Atlanta,
275 GA: US Department of Health and Human Services, CDC. doi:
276 10.15620/cdc:82532

277 4. Weiser JN, Ferreira DM, Paton JC. *Streptococcus pneumoniae*: transmission,
278 colonization and invasion. *Nat Rev Microbiol*. 2018;16(6):355–67. doi:
279 10.1038/s41579-018-0001-8

280 5. Kaplan EL, Top FH, Dudding BA, Wannamaker LW. Diagnosis of Streptococcal
281 Pharyngitis: Differentiation of Active Infection from the Carrier State in the
282 Symptomatic Child. *J Infect Dis* •. 1971;123(5):490–501. doi:
283 10.1093/infdis/123.5.490

284 6. Cunningham MW. Pathogenesis of Group A Streptococcal Infections. *Clin*
285 *Microbiol Rev*. 2000;13(3):470–511. doi: 10.1128/cmr.13.3.470-511.2000

286 7. Schuchat A. Group B Streptococcus. *Lancet*. 1999;353:51–6. doi:
287 10.1016/S0140-6736(98)07128-1

288 8. Campbell JR, Hillier SL, Krohn MA, Ferrieri P, Zaleznik DF, Baker CJ. Group B
289 Streptococcal colonization and serotype-specific immunity in pregnant women at
290 delivery. *Obstet Gynecol*. 2000;96(4):498–503. doi: 10.1016/s0029-
291 7844(00)00977-7

292 9. Nandyal RR. Update on Group B Streptococcal infections: perinatal and neonatal

- periods. *J Perinat Neonatal Nurs.* 2008;22(3):230–7. doi:
10.1097/01.JPN.0000333925.30328.f
10. Edwards MS, Rench MA, Haffar AA, Murphy MA, Desmond MM, Baker CJ. Long-term sequelae of Group B Streptococcal meningitis in infants. *J Pediatr.* 1985;106(5):717–22. doi: 0.1016/s0022-3476(85)80342-5
11. Armistead B, Oler E, Adams Waldorf K, Rajagopal L. The Double Life of Group B *Streptococcus*: Asymptomatic Colonizer and Potent Pathogen. *J Mol Biol.* 2019;431(16):2914–31. doi: 10.1016/j.jmb.2019.01.035
12. Wilkening R V, Federle MJ. Evolutionary Constraints Shaping *Streptococcus pyogenes*-Host Interactions. *Trends Microbiol.* 2017;25(7):562–72. doi: 10.1016/j.tim.2017.01.007
13. Mitchell AM, Mitchell TJ. *Streptococcus pneumoniae*: Virulence factors and variation. *Clin Microbiol Infect.* 2010;16(5):411–8. doi: 10.1111/j.1469-0691.2010.03183.x
14. Cohen M, Panos C. Membrane Lipid Composition of *Streptococcus pyogenes* and Derived L Form. *Biochemistry.* 1966;5(7):2385–92. doi: 10.1021/bi00871a031
15. Meiers M, Volz C, Eisel J, Maurer P, Henrich B, Hakenbeck R. Altered lipid composition in *Streptococcus pneumoniae* cpoA mutants. *BMC Microbiol.* 2014;14(1):1–12. doi: 10.1186/1471-2180-14-12
16. Trombe M-C, Lanelle M-A, Lanelle G. Lipid composition of aminopterin-resistant and sensitive strains of *Streptococcus pneumoniae*. *Biochim Biophys Acta - Lipids Lipid Metab.* 1979;574:290–300. doi: 10.1016/0005-2760(79)90010-9

17. Brundish DE, Shaw N, Baddiley J. The phospholipids of *Pneumococcus* I-192R, A.T.C.C. 12213. *Biochem J.* 1967;104:205–11. doi: 10.1042/bj1040205
18. Fischer W. The polar lipids of Group B *Streptococci*. II. Composition and positional distribution of fatty acids. *Biochim Biophys Acta.* 1977;487(1):89–104. doi: 10.1016/0005-2760(77)90046-7
19. Curtis J, Kim G, Wehr NB, Levine RL. Group B *Streptococcal* phospholipid causes pulmonary hypertension. *Proc Natl Acad Sci U S A.* 2003;100(9):5087–90. doi: 10.1073/pnas.0931493100
20. Goldfine H, Guan Z. Lipidomic Analysis of Bacteria by Thin-Layer Chromatography and Liquid Chromatography/Mass Spectrometry. In: Hydrocarbon and Lipid Microbiology Protocols. p. 125–39. doi: 10.1007/8623_2015_56
21. Doran KS, Engelson EJ, Khosravi A, Maisey HC, Fedtke I, Equils O, et al. Blood-brain barrier invasion by Group B *Streptococcus* depends upon proper cell-surface anchoring of lipoteichoic acid. *J Clin Invest.* 2005;115(9):2499–507. doi: 10.1172/JCI23829
22. Schneewind O, Missiakas D. Lipoteichoic acids, phosphate-containing polymers in the envelope of gram-positive bacteria. *J Bacteriol.* 2014;196(6):1133–42. doi: 10.1128/JB.01155-13
23. Joyce LR, Manzer HS, Da Mendonça JC, Villarreal R, Doran KS, Palmer KL, et al. *Streptococcus agalactiae* MprF synthesizes a novel cationic glycolipid that promotes brain entry and meningitis. *bioRxiv.* 2020; doi: <https://doi.org/10.1101/2020.12.01.406702>

24. Adams HM, Joyce LR, Guan Z, Akins RL, Palmer KL. *Streptococcus mitis* and *S. oralis* Lack a Requirement for CdsA, the Enzyme Required for Synthesis of Major Membrane Phospholipids in Bacteria. *Antimicrob Agents Chemother*. 2017;61(5):e02552-16. doi: 10.1128/AAC.02552-16
25. Joyce LR, Guan Z, Palmer KL. Phosphatidylcholine Biosynthesis in Mitis Group Streptococci via Host Metabolite Scavenging. *J Bacteriol*. 2019;201(22):e00495-19. doi: 10.1128/JB.00495-19
26. Van De Rijn I, Kessler RE. Growth characteristics of Group A Streptococci in a new chemically defined medium. *Infect Immun*. 1980;27(2):444–8. doi: 10.1128/IAI.27.2.444-448.1980
27. Chang JC, LaSarre B, Jimenez JC, Aggarwal C, Federle MJ. Two Group A Streptococcal peptide pheromones act through opposing rgg regulators to control biofilm development. *PLoS Pathog*. 2011;7(8):e1002190. doi: 10.1371/journal.ppat.1002190
28. Tan BK, Bogdanov M, Zhao J, Dowhan W, Raetz CRH, Guan Z. Discovery of a cardiolipin synthase utilizing phosphatidylethanolamine and phosphatidylglycerol as substrates. *Proc Natl Acad Sci*. 2012;109(41):16504–9. doi: 10.1073/pnas.1212797109
29. Li C, Tan BK, Zhao J, Guan Z. In vivo and in vitro synthesis of phosphatidylglycerol by an *Escherichia coli* cardiolipin synthase. *J Biol Chem*. 2016;291(48):25144–53. doi: 10.1074/jbc.M116.762070
30. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vázquez-Fresno R, et al. HMDB 4.0: the human metabolome database for 2018. *Nucleic Acids Res*.

- 2018;46(D1):D608–17. doi: 10.1093/nar/gkx1089
31. Ojala PJ, Hirvonen TE, Hermansson M, Somerharju P, Parkkinen J. Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. *J Leukoc Biol.* 2007;82(6):1501–9. doi: 10.1189/jlb.0507292
32. Sohlenkamp C, Geiger O. Bacterial membrane lipids: Diversity in structures and pathways. *FEMS Microbiol Rev.* 2016;40(1):133–59. doi: 10.1093/femsre/fuv008
33. Geiger O, López-Lara IM, Sohlenkamp C. Phosphatidylcholine biosynthesis and function in bacteria. *Biochim Biophys Acta - Mol Cell Biol Lipids.* 2013;1831:503–13. doi: 10.1016/j.bbalip.2012.08.009
34. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, et al. The human serum metabolome. *PLoS One.* 2011;6(2):e16957. doi: 10.1371/journal.pone.0016957
35. Goldfine H. The anaerobic biosynthesis of plasmalogens. *FEBS Lett.* 2017;591(18):2714–9. doi: 10.1002/1873-3468.12714
36. Mawatari S, Sasuga Y, Morisaki T, Okubo M, Emura T, Fujino T. Identification of plasmalogens in *Bifidobacterium longum*, but not in *Bifidobacterium animalis*. *Sci Rep.* 2020;10(1):1–10. doi: 10.1038/s41598-019-57309-7
37. Guan Z, Katzianer D, Zhu J, Goldfine H. *Clostridium difficile* contains plasmalogen species of phospholipids and glycolipids. *Biochim Biophys Acta.* 2014;1842(10):1353–9. doi: 10.1016/j.bbalip.2014.06.011
38. Gallego-García A, Monera-Girona AJ, Pajares-Martínez E, Bastida-Martínez E, Pérez-Castaño R, Iniesta AA, et al. A bacterial light response reveals an orphan desaturase for human plasmalogen synthesis. *Science (80-).*

385 2019;366(6461):128–32. doi: 10.1126/science.aay1436

386 39. Jackson DR, Cassilly CD, Plichta DR, Vlamakis H, Liu H, Melville SB, et al.

387 Plasmalogen Biosynthesis by Anaerobic Bacteria: Identification of a Two-Gene

388 Operon Responsible for Plasmalogen Production in *Clostridium perfringens*. *ACS*

389 *Chem Biol*. 2021;16(1):6–13. doi: 10.1021/acscchembio.0c00673

390 40. Zoeller RA, Morand OH, Raetz CRH. A possible role for plasmalogens in

391 protecting animal cells against photosensitized killing. *J Biol Chem*.

392 1988;263(23):11590–6. doi: 10.1016/S0021-9258(18)38000-1

393 41. Broniec A, Żądło A, Pawlak A, Fuchs B, Kłosiński R, Thompson D, et al.

394 Interaction of plasmenylcholine with free radicals in selected model systems. *Free*

395 *Radic Biol Med*. 2017;106:368–78. doi: 10.1016/j.freeradbiomed.2017.02.029

396

Figure 1. Glycolipid and phospholipid biosynthesis pathways in *S. pneumoniae*, *GAS*, and *GBS*. Genes of known or predicted function in each pathway are indicated. Lipids and substrates in black are common to all three species, in green are specific to *S. pneumoniae* (Spn), in red are specific to *GBS*, in blue are present in *S. pneumoniae* and *GAS*, and in purple are present in both *GAS* and *GBS*. DAG, diacylglycerol; Glc₂-DAG, diglucosyl-DAG; Gal-Glc-DAG, galactosyl-glucosyl-DAG; Lys-Glc-DAG, lysyl-glucosyl-DAG (synthesized by *mprF* (23)); PA, phosphatidic acid; CDP-DAG, cytidine diphosphate-DAG; PGP, PG-3-phosphate; PG, phosphatidylglycerol; Lys-PG, lysyl-phosphatidylglycerol; CL, cardiolipin; GPC, glycerophosphocholine; lysoPC, lyso-phosphatidylcholine; PC, phosphatidylcholine; Lyso-pPC, lyso-plasmany-PC; pPC, plasmany-PC. “?” denotes unidentified genes. It is currently unknown whether *GBS* scavenge lyso-pPC or pPC from human serum or if it is *de novo* synthesized from PC. This figure combines lipids and genes described in literature (14-19,21-25,32,33) and detected lipids from Table 1.

Figure 2. PC and Lys-PG detection when streptococci are cultured in different media. Shown are representative positive ESI mass spectra obtained during the LC retention time of 19 – 20.5 min indicating the presence or absence of PC, pPC, and Lys-PG in the membranes of A) *S. pneumoniae* TIGR4, B) *S. pyogenes* (GAS) MGAS315, and C) *S. agalactiae* (GBS) COH1 when cultured in: Panel 1, rich undefined medium; Panel 2, defined medium; and Panel 3, defined medium supplemented 5% v/v human serum. All cultures were performed in biological triplicate and representative spectra are shown.

Figure 3. LysoPC is scavenged by GAS and GBS to synthesize PC. A) GAS strain NZ131 cultured in defined medium supplemented with 100 μM GPC synthesizes a very low level of PC. B) GAS strain NZ131 grown in defined medium supplemented with 100 μM lysoPC (20:0) synthesizes PC. C) No PC is detected for GBS strain COH1 cultured in defined medium supplemented with 100 μM GPC. D) GBS strain COH1 cultured in defined medium supplemented with 100 μM lysoPC (20:0) synthesizes PC. Cultures were performed in biological triplicate and representative data are shown.

Table 1. Major lipids detected in *S. pneumoniae*, GAS, and GBS.

Species	Strain	Medium ¹	Detection of ²										
			DAG	MHDAG	DHDAG	PA	PG	CL	C ₅₅ -P	Lys-PG	L G D	PC	pPC
<i>S. pneumoniae</i> ³	D39	THB+0.5Y	+	+	+	+	+	+	+	-	-	+	-
		DM	+	+	+	+	+	+	+	-	-	-	-
		DM-HS	+	+	+	+	+	+	+	-	-	+	-
	TIGR4	THB+0.5Y	+	+	+	+	+	+	+	-	-	+	-
		DM	+	+	+	+	+	+	+	-	-	-	-
		DM-HS	+	+	+	+	+	+	+	-	-	+	-
<i>S. pyogenes</i> (GAS)	NZ131	THB+0.2Y	+	+	+	+	+	+	+	-	-	-	-
		DM	+	+	+	+	+	+	+	-	-	-	-
		DM-HS	+	+	+	+	+	+	+	-	-	+	-
	MGAS 315	THB+0.2Y	+	+	+	+	+	+	+	-	-	-	-
		DM	+	+	+	+	+	+	+	-	-	-	-
		DM-HS	+	+	+	+	+	+	+	-	-	+	-
<i>S. agalactiae</i> (GBS)	COH1	THB	+	+	+	+	+	+	+	+	+	-	-
		DM	+	+	+	+	+	+	+	+	+	-	-
		DM-HS	+	+	+	+	+	+	+	+	+	-	+
	A909	THB	+	+	+	+	+	+	+	+	+	-	-
		DM	+	+	+	+	+	+	+	+	+	-	-
		DM-HS	+	+	+	+	+	+	+	+	+	-	+

¹Todd-Hewitt Broth (THB); THB supplemented with 0.5% yeast extract (THB+0.5Y); THB supplemented with 0.2% yeast extract (THB+0.2Y); Streptococcal defined medium (DM), Streptococcal defined medium supplemented with 5% v/v human serum (DM-HS).

²Abbreviations and denotations: +, detected; -, undetected; DAG, diacylglycerol; MHDAG, monohexosyldiacylglycerol; DHDAG, dihexosyldiacylglycerol; PA, phosphatidic acid; PG, phosphatidylglycerol; CL, cardiolipin; C₅₅-P, undecaprenyl phosphate; Lys-PG, lysyl-phosphatidylglycerol; LGD, lysyl-glucosyl-DAG; PC, phosphatidylcholine; pPC, plasmalogen-PC.

³*S. pneumoniae* lipid profiles in THB+0.5Y and defined medium were originally described in Joyce LR *et al* 2019 (25).

Supplemental Text, Figures, and Table

***Streptococcus pneumoniae*, *S. pyogenes*, and *S. agalactiae* membrane phospholipid remodeling in response to human serum**

Luke. R. Joyce¹, Ziqiang Guan^{2#}, and Kelli L. Palmer^{1#}

¹Department of Biological Sciences, The University of Texas at Dallas, Richardson, TX, USA

²Department of Biochemistry, Duke University Medical Center, Durham, NC, USA

Running title: Phospholipid remodeling in pathogenic streptococci

#Corresponding authors

Ziqiang Guan: Ziqiang.Guan@duke.edu

Kelli Palmer: Kelli.Palmer@utdallas.edu

Supplemental Text S1. Materials and Methods

Growth curves

GAS and GBS were cultured overnight in defined medium and diluted to a starting OD_{600nm} of 0.05 in 15 mL pre-warmed defined medium supplemented with or without 5% v/v human serum. The OD_{600nm} was monitored manually every hour using a Thermo Scientific Genesys 30 spectrophotometer. For *S. pneumoniae*, early exponential phase defined medium overnight cultures, as described above, were diluted 1:50 into pre-warmed defined medium supplemented with or without 5% v/v human serum. *S. pneumoniae* cultures were incubated for 4 h before the OD_{600nm} was monitored every hour. Growth curves were performed in biological triplicate. Repeated measures two-way ANOVA with Bonferroni's multiple comparisons test was performed in GraphPad Prism version 8 for Windows, GraphPad software, San Diego, California, USA, www.graphpad.com.

Acidic Bligh-Dyer extractions.

Centrifugation was performed using a Sorvall RC6+ centrifuge. Cultures were pelleted at 4,280 x *g* for 5 min at room temperature. The supernatants were removed and stored at -80°C until acidic Bligh-Dyer lipid extractions were performed as described (1,2). Briefly, cell pellets were resuspended in 1X PBS (Sigma-Aldrich) and transferred to Corning Pyrex glass tubes with PTFE-lined caps (VWR), followed by 1:2 vol:vol chloroform:methanol addition. Single phase extractions were vortexed periodically and incubated at room temperature for 15 minutes before 500 x *g* centrifugation for 10 min. A two-phase Bligh-Dyer system was achieved by addition of 100 µl 37% HCL, 1 mL CHCl₃, and 900 µl of 1X PBS, which was then vortexed and centrifuged for 5 min at 500 x *g*. The lower phase was

removed to a new tube and dried under nitrogen before being stored at -80°C prior to lipidomic analysis.

Normal-Phase Liquid Chromatography-Electrospray Ionization/Mass Spectrometry (LC-ESI/MS).

Normal-phase LC-ESI/MS was performed on an Agilent 1200 quaternary LC system equipped with an Ascentis silica high-performance liquid chromatography (HPLC) column (5 µm; 25 cm by 2.1 mm; Sigma-Aldrich) as described previously (1–3). Briefly, mobile phase A consisted of chloroform-methanol-aqueous ammonium hydroxide (800:195:5, vol/vol), mobile phase B consisted of chloroform-methanol-water-aqueous ammonium hydroxide (600: 340:50:5, vol/vol), and mobile phase C consisted of chloroform-methanol-water-aqueous ammonium hydroxide (450:450:95:5, vol/vol/vol/vol). The elution program consisted of the following: 100% mobile phase A was held isocratically for 2 min, then linearly increased to 100% mobile phase B over 14 min, and held at 100% mobile phase B for 11 min. The LC gradient was then changed to 100% mobile phase C over 3 min, held at 100% mobile phase C for 3 min, and, finally, returned to 100% mobile phase A over 0.5 min and held at 100% mobile phase A for 5 min. The LC eluent (with a total flow rate of 300 ml/min) was introduced into the ESI source of a high-resolution TripleTOF5600 mass spectrometer (Sciex, Framingham, MA). Instrumental settings for positive-ion ESI and MS/MS analysis of lipid species were as follows: IS = 5,000 V, CUR = 20 psi, GSI = 20 psi, DP = +55 V, and FP = +150V. The MS/MS analysis used nitrogen as the collision gas. Data analysis was performed using Analyst TF1.5 software (Sciex, Framingham, MA).

Supplemental Figure S1. Growth characteristics of streptococci in the presence of 5% human serum. Growth curves in defined medium (DM) are shown in blue and defined medium supplemented 5% v/v human serum are shown in red. A) *S. pneumoniae* D39, B) *S. pneumoniae* TIGR4, C) *S. pyogenes* NZ131, D) *S. pyogenes* MGAS315, E) *S. agalactiae* A909, and F) *S. agalactiae* COH1. Manual OD_{600nm} readings were performed every hour. *S. pneumoniae* cultures were grown for 4 h before manual readings were performed. Growth curves were performed in biological triplicate. Mean and SD are indicated. Statistical analysis: A-F) repeated measures two-way ANOVA with Bonferroni's multiple comparisons test. * denotes p-value <0.05. *** denotes p-value <0.001.

Supplemental Figure S2. Positive ion mode total ion chromatograms (TIC) of streptococci grown in defined medium supplemented with or without 5% v/v human serum. Representative positive ion mode TIC for *S. pneumoniae* (top panels), *S. pyogenes* (middle panels), and *S. agalactiae* (bottom panels), indicate relative abundance of lipids present in the cell extract when streptococci are cultured in defined medium or defined medium supplemented with 5% v/v human serum. Cultures were performed in biological triplicate. Abbreviations: DAG, diacylglycerol; MHDAG, monohexosyldiacylglycerol; DHDAG, dihexosyldiacylglycerol; PG, phosphatidylglycerol; Lys-PG, lysyl-phosphatidylglycerol; LGD, lysyl-glucosyl-DAG; PC, phosphatidylcholine; '*' Denotes methylcarbamate, an extraction artifact of LGD.

Supplemental Figure S3. Confirmation of major PC and plasmanyl-PC species by MS/MS fragmentation. A) Chemical structure and fragmentation scheme of PC(16:0/18:2), B) MS/MS of m/z 758 for PC(16:0/18:2), C) Chemical structure and fragmentation scheme of pPC(16:0/16:0), and D) MS/MS of m/z 720 for pPC(16:0/16:0). MS/MS fragmentation, specifically m/z 482 fragment, is consistent with the structure of pPC present in the GBS.

99 **Table S1. Strains used in this study.**

Organism	Strain	Description	Ref
<i>S. pneumoniae</i>	D39	Wild-type <i>S. pneumoniae</i> strain, capsule serotype 2. Obtained from Michael Federle, University of Illinois at Chicago	(4)
	ATCC BAA-334 (TIGR4)	Wild-type <i>S. pneumoniae</i> strain, capsule serotype 4	(5)
<i>S. pyogenes</i> (GAS)	ATCC BAA-595 (MGAS315)	Wild-type <i>S. pyogenes</i> strain, M3 serotype	(6)
	ATCC BAA-1633 (NZ131)	Wild-type <i>S. pyogenes</i> strain, M49 serotype	(7,8)
<i>S. agalactiae</i> (GBS)	ATCC BAA-1176 (COH1)	Wild-type <i>S. agalactiae</i> strain, serotype III	(9)
	ATCC BAA-1138 (A909)	Wild-type <i>S. agalactiae</i> strain, serotype Ia	(10)

100

101

102

103 **References**

- 104 1. Joyce LR, Guan Z, Palmer KL. Phosphatidylcholine Biosynthesis in Mitis Group
105 Streptococci via Host Metabolite Scavenging. *J Bacteriol.* 2019;201(22):e00495-
106 19. doi: 10.1128/JB.00495-19
- 107 2. Tan BK, Bogdanov M, Zhao J, Dowhan W, Raetz CRH, Guan Z. Discovery of a
108 cardiolipin synthase utilizing phosphatidylethanolamine and phosphatidylglycerol
109 as substrates. *Proc Natl Acad Sci.* 2012;109(41):16504–9. doi:
110 10.1073/pnas.1212797109
- 111 3. Li C, Tan BK, Zhao J, Guan Z. In vivo and in vitro synthesis of
112 phosphatidylglycerol by an *Escherichia coli* cardiolipin synthase. *J Biol Chem.*
113 2016;291(48):25144–53. doi: 10.1074/jbc.M116.762070
- 114 4. Lanie JA, Ng WL, Kazmierczak KM, Andrzejewski TM, Davidsen TM, Wayne KJ,
115 et al. Genome sequence of Avery’s virulent serotype 2 strain D39 of
116 *Streptococcus pneumoniae* and comparison with that of unencapsulated
117 laboratory strain R6. *J Bacteriol.* 2007;189(1):38–51. doi: 10.1128/JB.01148-06
- 118 5. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, et al.
119 Complete genome sequence of a virulent isolate of *Streptococcus pneumoniae*.
120 *Science.* 2001;293(5529):498–506. doi: 10.1126/science.1061217
- 121 6. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK.
122 *Streptococcus pyogenes* causing toxic-shock-like syndrome and other invasive
123 diseases: clonal diversity and pyrogenic exotoxin expression. *Proc Natl Acad Sci*

U S A. 1991;88(7):2668–72. doi: 10.1073/pnas.88.7.2668

7. Simon D, Ferretti JJ. Electrotransformation of *Streptococcus pyogenes* with plasmid and linear DNA. *FEMS Microbiol Lett.* 1991;66(2):219–24. doi: 10.1016/0378-1097(91)90336-9

8. McShan WM, Ferretti JJ, Karasawa T, Suvorov AN, Lin S, Qin B, et al. Genome sequence of a nephritogenic and highly transformable M49 strain of *Streptococcus pyogenes*. *J Bacteriol.* 2008;190(23):7773–85. doi: 10.1128/JB.00672-08

9. Kuypers JM, Heggen LM, Rubens CE. Molecular analysis of a region of the Group B *Streptococcus* chromosome involved in type III capsule expression. *Infect Immun.* 1989;57(10):3058–65. doi: 10.1128/IAI.57.10.3058-3065.1989

10. Lancefield RC, McCarty M, Everly WN. Multiple mouse-protective antibodies directed against Group B Streptococci. Special reference to antibodies effective against protein antigens. *J Exp Med.* 1975;142(1):165–79. doi: 10.1084/jem.142.1.165